

Summit Therapeutics plc

("Summit" or the "Company")

SUMMIT THERAPEUTICS TO PRESENT AT 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

Oxford, UK, 7 September 2016 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and *Clostridium difficile* infection, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference, 13 September 2016 at 2:35pm EDT in New York City.

A live audio webcast of the presentation will be available through the Investors section on the Company's website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, *Clostridium difficile* infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

Tel: +44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP

(Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7148 7900

N+1 Singer

(Broker)
Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications

(US media contact)
Chris Erdman / Karen Sharma

Tel: +1 781 235 3060
cerdman@macbiocom.com
ksharma@macbiocom.com

Consilium Strategic Communications

(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-